Title

A Pilot Study of TRV130 for the Treatment of Fracture Pain
A Phase 2, Open-label Pilot Study of TRV130 for the Treatment of Moderate to Severe Acute Pain Associated With Long Bone Fracture
  • Phase

    Phase 2
  • Study Type

    Interventional
  • Indication/Condition

    Pain
  • Study Participants

    1
The primary objective is to evaluate the analgesic efficacy of TRV130 for moderate to severe acute pain in patients presenting to the emergency department (ED) with a suspected/known, unilateral, closed long bone fracture.
This study is designed to evaluate the analgesic efficacy of TRV130 for the treatment of moderate to severe acute pain associated with a long bone fracture in patients presenting to the ED. The safety and tolerability of TRV130 will also be evaluated in this open-label pilot study.
Study Started
Oct 20
2015
Primary Completion
Oct 23
2015
Study Completion
Oct 23
2015
Results Posted
Sep 07
2020
Last Update
Sep 07
2020

Drug TRV130

Drug

TRV130 Experimental

Drug: TRV130

Criteria

Inclusion Criteria:

Age 18-65 years, inclusive
Has a suspected/known, unilateral, closed fracture of either: radius, ulna (or both) OR tibia, fibula (or both) BUT not fractures in more than 1 extremity
Able to understand and comply with study procedures and requirements, and provide written informed consent

Exclusion Criteria:

Significant concomitant head, chest, or abdominal trauma
Multiple extremity trauma
Open fracture
Clinically significant medical condition or history of such condition that may place the patient at an unacceptable risk in the trial, may interfere with the interpretation of efficacy, safety, or tolerability data obtained in the trial, or may interfere with the absorption, distribution, metabolism, or excretion of drugs

Summary

TRV130

All Events

Event Type Organ System Event Term

Proportion of Patients Achieving Clinical Response, Defined as Achieving a NPRS <= 3, Without Requiring Rescue Pain Medication.

Pain intensity will be evaluated using an 11-point numeric pain rating scale administered over 3 hours

TRV130

Time Weighted Average Change in NPRS

Pain intensity will be evaluated using an 11-point numeric pain rating scale administered over 3 hours

TRV130

Time to First NPRS <= 3

Pain intensity will be evaluated using an 11-point numeric pain rating scale administered over 3 hours

TRV130

Safety Assessments

Safety assessments include adverse events, vital sign measurements, physical examination findings, and clinical laboratory assessments.

TRV130

Age, Continuous

30
years (Mean)
Standard Deviation: 0

Age, Categorical

Ethnicity (NIH/OMB)

Race (NIH/OMB)

Region of Enrollment

Sex: Female, Male

Overall Study

TRV130